Document

6-K 1 q12026sophiageneticssa6-k.htm 6-K Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026.

____________________________________

Commission File Number: 001-40627

SOPHiA GENETICS SA

(Exact name of registrant as specified in its charter)

La Pièce 12

CH-1180 Rolle

Switzerland

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F

Form 40-F

SIGNATURE

This Report on Form 6-K (other than Exhibit 99.3 hereto), including Exhibits 99.1 and 99.2 hereto, shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration No. 333-280060; Registration No. 333-289266; Registration No. 333-289270; Registration No. 333-293970) and on Form S-8 (Registration No. 333-258121; Registration No. 333-258122 and Registration No.333-288625) of SOPHiA GENETICS SA and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


		SOPHiA GENETICS SA
Date:	May 5, 2026

		By:	/s/ Daan van Well
		Name:	Daan van Well
		Title:	Chief Legal and Regulatory Officer

EXHIBIT INDEX


Exhibit No.			Description
99.1			Unaudited interim condensed consolidated financial statements as of and for the three months ended March 31, 2026
99.2			Management’s discussion and analysis of financial condition and results of operations
99.3			Press release dated May 5, 2026

SEC Form 6-K filed by SOPHiA GENETICS SA